Extrawell Pharmaceutical Holdings (HKSE:00858) Total Current Liabilities: HK$39.59 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Extrawell Pharmaceutical Holdings Total Current Liabilities?

Extrawell Pharmaceutical Holdings HKSE:00858 Total Current Liabilities is HK$39.59 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Extrawell Pharmaceutical Holdings's total current liabilities for the quarter that ended in Mar. 2026 was HK$39.59

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Extrawell Pharmaceutical Holdings Total Current Liabilities Related Terms

Extrawell Pharmaceutical Holdings Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Extrawell Pharmaceutical Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Extrawell Pharmaceutical Holdings Total Current Liabilities Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.06 57.01 51.37 48.50 39.59

Extrawell Pharmaceutical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.37 49.97 48.50 49.10 39.59

Extrawell Pharmaceutical Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Extrawell Pharmaceutical Holdings's Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=24.53+1.169
+Other Current Liabilities+Current Deferred Liabilities
=10.327+3.564
=39.59

Extrawell Pharmaceutical Holdings's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=24.53+1.169
+Other Current Liabilities+Current Deferred Liabilities
=10.327+3.564
=39.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of HK$39.59 Mil mean?
Extrawell Pharmaceutical Holdings (HKSE:00858) has a Total Current Liabilities of HK$39.59 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Extrawell Pharmaceutical Holdings and its competitors.
Is Extrawell Pharmaceutical Holdings' Total Current Liabilities too high?
Extrawell Pharmaceutical Holdings' current Total Current Liabilities is HK$39.59 Mil.
How does Extrawell Pharmaceutical Holdings' Total Current Liabilities compare to ZTS?
Extrawell Pharmaceutical Holdings' Total Current Liabilities of HK$39.59 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Extrawell Pharmaceutical Holdings and its competitors. Extrawell Pharmaceutical Holdings's current Total Current Liabilities is HK$39.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 68% above its estimated fair value. The current Total Current Liabilities is HK$39.59 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current Total Current Liabilities is HK$39.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Extrawell Pharmaceutical Holdings Business Description

Address 979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.